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colleagues suggest that protection of macrovascular 
compared with microvascular disease has a diﬀ erent 
temporal proﬁ le, but in fact there is evidence against 
this assertion. In blood-pressure-lowering trials,5,6 both 
cardiovascular and renal outcomes were detected within 
several years, and there was a marked similarity between 
cardiovascular and renal protection. The response from 
professionals in the community to the primary Look 
AHEAD publication on cardiovascular outcomes focused 
on the power of the study,7 and this would also be an 
appropriate response to the present renal outcome 
substudy. Kowler and colleagues3 did report a post-hoc 
power calculation, which would be suﬃ  cient—however, 
the events used for the power calculation are not hard 
renal endpoints. Notably, cardiovascular and renal hard 
outcome studies now need around 9000 high-risk 
patients to establish a 15% risk reduction. 
The renal protective mechanism of weight loss is 
complex. Overweight is associated with cardiovascular 
and renal risk, but also with cardiovascular and renal 
risk factors such as high blood pressure, high lipid 
concentrations, and albuminuria reduction.8 Weight loss 
is also associated with blood pressure and albuminuria 
reduction. Therefore, to conclude that the reported 
renal protection from weight reduction is caused by 
an antihypertensive eﬀ ect is tempting. Additionally, 
is caloric restriction the cause of the renal outcome 
changes? Or is the cause restriction of sodium intake or 
protein intake, both of which have been associated with 
renal protection?9,10 Data on urinary sodium or urea, or 
both, would be helpful to resolve why the intervention 
did not aﬀ ect cardiovascular outcomes yet did protect 
the kidneys. These data would also inform whether it 
is weight loss itself or changes in biomarkers that drive 
cardiovascular and renal changes in response to lifestyle 
interventions. Such information would better guide us 
in designing improved approaches for renal protection 
in patients with type 2 diabetes.
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 Saturated fatty acids and type 2 diabetes: more evidence to 
re-invent dietary guidelines 
Although saturated fatty acids (SFAs) are undoubt-
edly biologically active, several complexities preclude 
over simpliﬁ ed predictions of their health eﬀ ects. 
First, although attention has historically focused 
on blood LDL cholesterol, SFAs aﬀ ect many other 
physiological pathways, including other blood lipids 
and lipoproteins1 and glucose–insulin responses.2 
Second, diﬀ erent SFAs exist, with chain lengths 
ranging from 6 to 22 or more carbon atoms, and they 
have varying biological eﬀ ects. Third, the relative 
eﬀ ects of these SFAs also depend on the comparison 
nutrient, for example, other speciﬁ c fatty acids, types 
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of carbohydrate, or proteins.1,3 Fourth, dietary SFAs 
are obtained from remarkably diverse foods—red 
meat, poultry, processed meats, yoghurt, milk, cheese, 
butter, vegetable oils, and nuts, among others—
that contain many other components that could 
modify their overall health eﬀ ects. Finally, SFAs are 
derived not only from diet but also from endogenous 
synthesis (hepatic de-novo lipogenesis) in response to 
large, rapidly delivered doses of carbohydrate or total 
calories, which is especially important for even-chain 
SFAs (eg, 14:0 and 16:0).
In recent years, evidence for these complexities has 
revitalised scientiﬁ c interest and investigation into the 
eﬀ ects of SFAs on coronary heart disease4 and type 2 
diabetes.5 In The Lancet Diabetes & Endocrinology, Nita 
Forouhi and colleagues present an important new study 
assessing plasma levels of SFAs and new-onset type 2 
diabetes.6 This prospective investigation, nested within 
the EPIC study, included 12 403 cases of type 2 diabetes 
derived from 340 234 people across eight European 
countries. Plasma phospholipid SFAs were measured 
at baseline, providing an objective assessment of nine 
diﬀ erent circulating SFAs. After adjustment for other 
risk factors, odd-chain SFAs were associated with a 
lower incidence of type 2 diabetes (HR [95% CI] per 
1 SD diﬀ erence: pentadecanoic acid 0·79 [0·73–0·85] 
and heptadecanoic acid 0·67 [0·63–0·71]), as were 
very-long-chain SFAs (HRs ranged from 0·72 to 0·81, 
with 95% CIs of 0·61–92). Conversely, even-chain SFAs 
were associated with an increased incidence of type 2 
diabetes (HR [95% CI] per 1 SD diﬀ erence: myristic acid 
1·15 [95% CI 1·09–1·22], palmitic acid 1·26 [1·15–1·37], 
and stearic acid 1·06 [1·00–1·13]). Results were con-
sistent across the eight countries and in sensitivity 
analyses. When dietary correlates were assessed, odd-
chain SFAs were associated most strongly with dairy 
products, as expected. Even-chain SFAs correlated more 
strongly with drivers of de-novo lipogenesis, including 
alcohol, soft drinks, and potatoes, than with direct 
dietary sources such as meat, butter, or cheese. Very-
long-chain SFAs had weaker associations with diet than 
the other SFAs (although the strongest association 
was with nuts/seeds, which is one dietary source), 
which suggests that metabolic determinants could be 
especially important for plasma long-chain SFAs. 
Several strengths of this research are evident, 
including its prospective subcohort design, its 
evaluation of several countries, the inclusion of a 
very large number of cases, the adjustment for many 
standardised covariates, and the assessment of dietary 
correlates. As the authors conclude, diﬀ erent SFAs 
were associated with type 2 diabetes in opposing 
directions, which provides clear evidence that SFAs are 
not a single homogeneous group. 
What are the implications of this study? First, these 
results add to growing evidence that dairy fat might 
reduce insulin resistance and type 2 diabetes,7 beneﬁ ts 
that might be greatest for cheese and yoghurt.8 Further 
research is needed to establish whether odd-chain 
SFAs have direct physiological beneﬁ ts or are merely 
correlates of other beneﬁ cial compounds in dairy fat or 
other aspects of dairy fat-rich foods, such as probiotics 
or fermentation. Whatever the mechanism, these 
results add further challenges to prevailing dietary 
guidelines that recommend low-fat dairy products on 
the basis of the postulated bone beneﬁ ts of calcium 
and theorised harms of total saturated fat content, 
rather than consideration of the complex nutrients and 
preparation methods of diﬀ erent dairy foods and the 
evidence for their direct health eﬀ ects. 
Second, the results conﬁ rm previous evidence that 
tissue concentrations of even-chain SFAs are linked to 
metabolic dysfunction—palmitic acid (16:0) seems to 
be especially harmful in animal and in-vitro models—
and that, as reviewed elsewhere,9 these SFAs are mainly 
derived from endogenous hepatic synthesis, driven by 
consumption of starch, sugars, and alcohol. Thus, the 
present ﬁ ndings support adverse metabolic eﬀ ects 
of reﬁ ned carbohydrates and sugars and could also 
indicate, at least in part, reverse causation: underlying 
baseline metabolic dysfunction would increase de-
novo lipogenesis, hepatic steatosis, circulating amounts 
of even-chain SFAs, and the future development of 
type 2 diabetes. Notably, the careful evaluation of 
dietary correlates was crucial to avoid prior erroneous 
interpretations from EPIC that circulating amounts 
of even-chain SFAs provide inference on eﬀ ects of 
their direct dietary intakes.10 Additionally, the present 
ﬁ ndings draw attention to the need for investigation of 
the intriguing and remarkably understudied very-long-
chain SFAs, the determinants (dietary and metabolic) 
and health eﬀ ects of which remain largely unknown. 
The consistent evidence for diﬀ ering health eﬀ ects 
of diﬀ erent SFAs, and their varying endogenous versus 
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dietary determinants, remains under-recognised by many 
scientists, clinicians, media writers, and policy makers. 
Taken together with other advances in nutritional 
science, now is the time to redesign our process of setting 
dietary guidelines. We need to move away from unhelpful 
classiﬁ cations and policies based on crude groupings 
of merely chemically related nutrients (eg, total 
saturated fat) and their predicted or postulated eﬀ ects 
on risk—which, in addition to scientiﬁ c dubiousness, 
create confusion for consumers and opportunities for 
manipulation by industry—and towards food-based 
guidelines that mainly consider prospective evidence for 
eﬀ ects on clinical endpoints.
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